{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T16:33:33Z","timestamp":1743006813116,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":132,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783540857716"},{"type":"electronic","value":"9783540857723"}],"license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-540-85772-3_15","type":"book-chapter","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T09:10:18Z","timestamp":1303290618000},"page":"307-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Supportive Therapy in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,19]]},"reference":[{"issue":"Suppl 3","key":"15_CR1_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.13-S3-33","volume":"13","author":"MS Aapro","year":"2008","unstructured":"Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33\u201336","journal-title":"Oncologist"},{"key":"15_CR2_15","first-page":"128","volume":"61","author":"N Abildgaard","year":"1998","unstructured":"Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H et al (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Med 61:128\u2013134","journal-title":"Eur J Med"},{"issue":"8","key":"15_CR3_15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150(8):1693\u20131695","journal-title":"Arch Intern Med"},{"key":"15_CR4_15","doi-asserted-by":"crossref","unstructured":"Amato A, Pescatori M (2006) Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev (1):CD005033. Review","DOI":"10.1002\/14651858.CD005033.pub2"},{"key":"15_CR5_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9343(96)90006-6","volume":"100","author":"EJ Anaissie","year":"1996","unstructured":"Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D et al (1996) Randomized comparison between antibiotics alone and antibiotics plus granulocyte\u2013macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 100:17\u201323","journal-title":"Am J Med"},{"key":"15_CR6_15","unstructured":"Anderson KC and NCCN Multiple Myeloma Panel Members (2009) NCCN Clinical practice guidelines in oncology: multiple myeloma. Version 2 http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf"},{"issue":"10","key":"15_CR7_15","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al (2006) Inter-groupe Francophone du Myelome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289\u20133294","journal-title":"Blood"},{"issue":"36","key":"15_CR8_15","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 \u2013 Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23(36):9219\u20139226","journal-title":"J Clin Oncol"},{"key":"15_CR9_15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001813-199606000-00003","volume":"7","author":"A Aviles","year":"1996","unstructured":"Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-Maqueo JC (1996) Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 7:392\u2013397","journal-title":"Anticancer Drugs"},{"key":"15_CR10_15","doi-asserted-by":"crossref","first-page":"ii1229","DOI":"10.1016\/S0140-6736(87)91850-2","volume":"330","author":"F Balkwill","year":"1987","unstructured":"Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H et al (1987) Evidence for tumor necrosis factor\/cachectin production in cancer. Lancet 330:ii1229\u2013ii1232","journal-title":"Lancet"},{"key":"15_CR11_15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V76.4.677.677","volume":"76","author":"B Barlogie","year":"1990","unstructured":"Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A et al (1990) High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 76:677\u2013680","journal-title":"Blood"},{"key":"15_CR12_15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0889-8588(05)70435-4","volume":"11","author":"R Bataille","year":"1997","unstructured":"Bataille R, Manolagas SC, Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11:349\u2013361","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"15_CR13_15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000097464","volume":"117","author":"R Baz","year":"2007","unstructured":"Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, et al (2007) Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 117(3):162\u2013167","journal-title":"Acta Haematol"},{"key":"15_CR14_15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2141.1992.tb06939.x","volume":"82","author":"Y Beguin","year":"1992","unstructured":"Beguin Y, Yerna M, Loo M, Weber M, Fillet G (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648\u2013653","journal-title":"Br J Haematol"},{"issue":"8","key":"15_CR15_15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","volume":"9","author":"AR Belch","year":"1991","unstructured":"Belch AR, Bergsagel DE, Wilson K, O\u2019Reilly S, Wilson J, Sutton D, et al (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9(8):1397\u20131402","journal-title":"J Clin Oncol"},{"issue":"1","key":"15_CR16_15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","volume":"10","author":"JR Berenson","year":"2005","unstructured":"Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10(1):52\u201362","journal-title":"Oncologist"},{"key":"15_CR17_15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488\u2013493","journal-title":"N Engl J Med"},{"key":"15_CR18_15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593\u2013602","journal-title":"J Clin Oncol"},{"key":"15_CR19_15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191\u20131200","journal-title":"Cancer"},{"key":"15_CR20_15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0003-4975(97)00858-8","volume":"64","author":"A Bernard","year":"1997","unstructured":"Bernard A, Caillot D, Couaillier JF, Casasnovas O, Guy H, Favre JP (1997) Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 64:1441\u20131447","journal-title":"Ann Thorac Surg"},{"key":"15_CR21_15","first-page":"219","volume":"42","author":"R Bezares","year":"1997","unstructured":"Bezares R, Murro H, Diaz A, Cavagnaro F, Caviglia D, Santome J (1997) Prevention of infections in patients with lymphoproliferative syndromes and myeloma by nebulization of an IgA concentrate [In Spanish]. Sangre 42:219\u2013222","journal-title":"Sangre"},{"issue":"5","key":"15_CR22_15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","volume":"77","author":"G Birgegard","year":"2006","unstructured":"Birgegard G, Gascon P, Ludwig H (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 77(5):378\u2013386","journal-title":"Eur J Haematol"},{"issue":"4","key":"15_CR23_15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","volume":"18","author":"J Blad\u00e9","year":"2005","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L (2005) Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 18(4):635\u2013652","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"15_CR24_15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Fernandez-Llama P, Bosch F et al (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158(17):1889\u20131893","journal-title":"Arch Intern Med"},{"issue":"Suppl 11","key":"15_CR25_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/sonc.2001.25426","volume":"28","author":"JJ Body","year":"2001","unstructured":"Body JJ (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28(Suppl 11):49\u201353","journal-title":"Semin Oncol"},{"key":"15_CR26_15","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","volume":"16","author":"JJ Body","year":"1998","unstructured":"Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H et al (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16:3890\u20133899","journal-title":"J Clin Oncol"},{"issue":"10","key":"15_CR27_15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","volume":"98","author":"J Bohlius","year":"2006","unstructured":"Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98(10):708\u2013714","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"15_CR28_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","volume":"43","author":"C Bokemeyer","year":"2007","unstructured":"Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P, European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258\u2013270, Epub 2006 Dec 19. Review","journal-title":"Eur J Cancer"},{"key":"15_CR29_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","volume":"101","author":"H Brincker","year":"1998","unstructured":"Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M et al (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 101:280\u2013286","journal-title":"Br J Haematol"},{"key":"15_CR30_15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","volume":"85","author":"A Carano","year":"1990","unstructured":"Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC (1990) Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456\u2013461","journal-title":"J Clin Invest"},{"key":"15_CR31_15","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"86","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood 86:4446\u20134453","journal-title":"Blood"},{"issue":"3","key":"15_CR32_15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","volume":"122","author":"M Cazzola","year":"2003","unstructured":"Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122(3):386\u2013393","journal-title":"Br J Haematol"},{"key":"15_CR33_15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059\u20131063","journal-title":"Lancet"},{"key":"15_CR34_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3322\/canjclin.44.5.263","volume":"44","author":"NI Cherny","year":"1994","unstructured":"Cherny NI, Portenoy RK (1994) The management of cancer pain. CA Cancer J Clin 44:263\u2013303","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"15_CR35_15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","volume":"143","author":"WF Clark","year":"2005","unstructured":"Clark WF, Stewart AK, Rock GA et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"15_CR36_15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","volume":"10","author":"RE Coleman","year":"1999","unstructured":"Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H et al (1999) Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10:311\u2013316","journal-title":"Ann Oncol"},{"issue":"4","key":"15_CR37_15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","volume":"95","author":"J Crawford","year":"2002","unstructured":"Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4):888\u2013895","journal-title":"Cancer"},{"key":"15_CR38_15","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","volume":"98","author":"PI Croucher","year":"2001","unstructured":"Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A et al (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534\u20133540","journal-title":"Blood"},{"key":"15_CR39_15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","volume":"28","author":"F Dammacco","year":"1998","unstructured":"Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G et al (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127\u2013134","journal-title":"Int J Clin Lab Res"},{"key":"15_CR40_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172\u2013179","journal-title":"Br J Haematol"},{"issue":"8","key":"15_CR41_15","first-page":"449","volume":"2","author":"A Daragon","year":"1993","unstructured":"Daragon A, Humez C, Michot C, Le Loet X, Grosbois B, Pouyol F, et al (1993) Treatment of multiple myeloma with etidronate: results of a multicenter double-blind study. Groupe d\u2019Etudes et de Recherches sur le My\u00e9lome (GERM). Eur J Med 2(8):449\u2013452","journal-title":"Eur J Med"},{"key":"15_CR42_15","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","volume":"16","author":"GD Demetri","year":"1998","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412\u20133425","journal-title":"J Clin Oncol"},{"key":"15_CR43_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1990.tb00374.x","volume":"44","author":"H Denz","year":"1990","unstructured":"Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J et al (1990) Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 44:186\u2013189","journal-title":"Eur J Haematol"},{"key":"15_CR44_15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blad\u00e9 J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485\u20131493","journal-title":"Leukemia"},{"issue":"1","key":"15_CR45_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20(1):117\u2013120","journal-title":"Ann Oncol"},{"key":"15_CR46_15","doi-asserted-by":"crossref","unstructured":"Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H et al Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2001: CD003188","DOI":"10.1002\/14651858.CD003188"},{"issue":"4","key":"15_CR47_15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","volume":"82","author":"BG Durie","year":"2007","unstructured":"Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82(4):516\u2013517, author reply 517\u2013518","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"15_CR48_15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48(2):337\u2013341","journal-title":"Leuk Lymphoma"},{"key":"15_CR49_15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.V79.8.1987.1987","volume":"79","author":"WC Faquin","year":"1992","unstructured":"Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987\u20131994","journal-title":"Blood"},{"key":"15_CR50_15","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875\u20132882","journal-title":"J Clin Oncol"},{"key":"15_CR51_15","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","volume":"155","author":"JP Garton","year":"1995","unstructured":"Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G et al (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069\u20132074","journal-title":"Arch Intern Med"},{"issue":"19 Suppl","key":"15_CR52_15","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1093\/annonc\/mdn107","volume":"2","author":"R Greil","year":"2008","unstructured":"Greil R, Psenak O, Roila F, ESMO Guidelines Working Group (2008) Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2(19 Suppl):ii116\u2013ii118","journal-title":"Ann Oncol"},{"key":"15_CR53_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00366899","volume":"1","author":"SA Grossman","year":"1993","unstructured":"Grossman SA (1993) Undertreatment of cancer pain: barriers and remedies. Support Care Cancer 1:74\u201378","journal-title":"Support Care Cancer"},{"key":"15_CR54_15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0885-3924(91)90518-9","volume":"6","author":"SA Grossman","year":"1991","unstructured":"Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6:53\u201357","journal-title":"J Pain Symptom Manage"},{"key":"15_CR55_15","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"JH Han","year":"2001","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349\u20133353","journal-title":"Blood"},{"key":"15_CR56_15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","volume":"48","author":"RM Hargreaves","year":"1995","unstructured":"Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C et al (1995) Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 48:260\u2013266","journal-title":"J Clin Pathol"},{"issue":"Supplement 2","key":"15_CR57_15","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1093\/annonc\/mdn088","volume":"19","author":"JL Harousseau","year":"2008","unstructured":"Harousseau JL, Dreyling M, On behalf of the ESMO Guidelines Working Group (2008) Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Supplement 2):ii55\u2013ii57","journal-title":"Ann Oncol"},{"key":"15_CR58_15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01682343","volume":"4","author":"HA Harvey","year":"1996","unstructured":"Harvey HA, Lipton A (1996) The role of bisphosphonates in the treatment of bone metastases \u2013 the U.S. experience. Support Care Cancer 4:213\u2013217","journal-title":"Support Care Cancer"},{"issue":"3","key":"15_CR59_15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122(3):394\u2013403","journal-title":"Br J Haematol"},{"issue":"1","key":"15_CR60_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139(1):101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"15_CR61_15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","volume":"92","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460\u2013470","journal-title":"Cancer"},{"issue":"3","key":"15_CR62_15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.2006080821","volume":"18","author":"CA Hutchison","year":"2007","unstructured":"Hutchison CA, Cockwell P, Reid S et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18(3):886\u2013895","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"15_CR63_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.10-90001-14","volume":"10","author":"GH Jackson","year":"2005","unstructured":"Jackson GH (2005) Renal safety of ibandronate. Oncologist 10(Suppl 1):14\u201318","journal-title":"Oncologist"},{"key":"15_CR64_15","first-page":"282","volume":"13","author":"DR Jacobson","year":"1986","unstructured":"Jacobson DR, Zolla-Pazner S (1986) Immunosuppression and infection in multiple myeloma. Semin Oncol 13:282\u2013290","journal-title":"Semin Oncol"},{"key":"15_CR65_15","doi-asserted-by":"crossref","unstructured":"Katodritou E, Speletas M, Kapetanos D, Zervas K, Pavlitou A et al (2004) Evaluation of traditional and novel predictive markers of anemia response to recombinant human erythropoietin (rh-Epo) in patients with multiple myeloma and lymphoma: emerging role of functional iron deficiency. ASH Congress San Diego 2004. Blood 104(11):abstract 3690","DOI":"10.1182\/blood.V104.11.3690.3690"},{"issue":"9","key":"15_CR66_15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","volume":"83","author":"E Katodritou","year":"2008","unstructured":"Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, et al (2008) Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83(9):697\u2013701","journal-title":"Am J Hematol"},{"key":"15_CR67_15","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.4049\/jimmunol.148.8.2483","volume":"148","author":"JB Klein","year":"1992","unstructured":"Klein JB, Scherzer JA, McLeish KR (1992) IFN-gamma enhances expression of formyl peptide receptors and guanine nucleotide-binding proteins by HL-60 granulocytes. J Immunol 148:2483\u20132488","journal-title":"J Immunol"},{"issue":"19","key":"15_CR68_15","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080","journal-title":"N Engl J Med"},{"issue":"12","key":"15_CR69_15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMoa070403","volume":"358","author":"CG Koch","year":"2008","unstructured":"Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH (2008) Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 358(12):1229\u20131239","journal-title":"N Engl J Med"},{"key":"15_CR70_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1700621","volume":"19","author":"K Kolbe","year":"1997","unstructured":"Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE (1997) Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19:143\u2013147","journal-title":"Bone Marrow Transplant"},{"key":"15_CR71_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","volume":"50","author":"RA Kyle","year":"1975","unstructured":"Kyle RA (1975) Multiple myeloma, review of 869 cases. Mayo Clin Proc 50:29\u201340","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"15_CR72_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21\u201333","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"15_CR73_15","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K (2007) American Society of Clinical Oncology clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464\u20132472","journal-title":"J Clin Oncol"},{"issue":"8","key":"15_CR74_15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"MQ Lacy","year":"2006","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR et al (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81(8):1047\u20131053","journal-title":"Mayo Clin Proc"},{"key":"15_CR75_15","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"R Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049\u20131052","journal-title":"Lancet"},{"key":"15_CR76_15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/42.4.497","volume":"42","author":"C Lass-Florl","year":"1998","unstructured":"Lass-Florl C, Kofler G, Kropshofer G, Hermans J, Kreczy A, Dierich MP et al (1998) In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42:497\u2013502","journal-title":"J Antimicrob Chemother"},{"key":"15_CR77_15","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","volume":"73","author":"C Leitgeb","year":"1994","unstructured":"Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535\u20132542","journal-title":"Cancer"},{"issue":"3 Suppl 8","key":"15_CR78_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/sonc.2002.33533","volume":"29","author":"H Ludwig","year":"2002","unstructured":"Ludwig H (2002) Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 29(3 Suppl 8):45\u201354","journal-title":"Semin Oncol"},{"issue":"4 Suppl 6","key":"15_CR79_15","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminhematol.2006.08.008","volume":"43","author":"H Ludwig","year":"2006","unstructured":"Ludwig H (2006) Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol 43(4 Suppl 6):S13\u2013S17","journal-title":"Semin Hematol"},{"issue":"24","key":"15_CR80_15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","volume":"322","author":"H Ludwig","year":"1990","unstructured":"Ludwig H, Fritz E, Kotzmann H, H\u00f6cker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322(24):1693\u20131699","journal-title":"N Engl J Med"},{"key":"15_CR81_15","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","volume":"113","author":"H Ludwig","year":"2009","unstructured":"Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A (2009) Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma. Blood 113:3435\u20133442","journal-title":"Blood"},{"key":"15_CR82_15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-121-7-199410010-00004","volume":"121","author":"DW Maher","year":"1994","unstructured":"Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M et al (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492\u2013501","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"15_CR83_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","volume":"28","author":"PP Major","year":"2001","unstructured":"Major PP, Coleman RE (2001) Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol 28(Suppl 3):17\u201324","journal-title":"Semin Oncol"},{"issue":"9","key":"15_CR84_15","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1097\/CCM.0b013e3181844677","volume":"36","author":"PE Marik","year":"2008","unstructured":"Marik PE, Corwin HL (2008) Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 36(9):2667\u20132674","journal-title":"Crit Care Med"},{"key":"15_CR85_15","first-page":"214","volume":"73","author":"M Massaia","year":"1988","unstructured":"Massaia M, Dianzani U, Bianchi A, Camponi A, Boccadoro M, Pileri A (1988) Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol 73:214\u2013218","journal-title":"Clin Exp Immunol"},{"key":"15_CR86_15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0041-1345(96)00444-7","volume":"29","author":"J Mattsson","year":"1997","unstructured":"Mattsson J, Ringden O, Aschan J, Barkholt L, Dalianis T, Hagglund H et al (1997) A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate. Transplant Proc 29:735\u2013736","journal-title":"Transplant Proc"},{"key":"15_CR87_15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","volume":"113","author":"EV McCloskey","year":"2001","unstructured":"McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035\u20131043","journal-title":"Br J Haematol"},{"key":"15_CR88_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","volume":"100","author":"EV McCloskey","year":"1998","unstructured":"McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317\u2013325","journal-title":"Br J Haematol"},{"issue":"9","key":"15_CR89_15","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20(9):2353\u20132359","journal-title":"J Clin Oncol"},{"key":"15_CR90_15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/94.4.248","volume":"94","author":"J Michalowski","year":"2002","unstructured":"Michalowski J (2002) COX-2 inhibitors: cancer trials test new uses for pain drug. J Natl Cancer Inst 94:248\u2013249","journal-title":"J Natl Cancer Inst"},{"key":"15_CR132_15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davles FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989\u20131999","journal-title":"Lancet"},{"key":"15_CR91_15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10428199809068565","volume":"29","author":"P Musto","year":"1998","unstructured":"Musto P (1998) The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. Leuk Lymphoma 29:283\u2013291","journal-title":"Leuk Lymphoma"},{"key":"15_CR92_15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","volume":"58","author":"P Musto","year":"1997","unstructured":"Musto P, Falcone A, D\u2019Arena G et al (1997) Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58:314\u2013319","journal-title":"Eur J Haematol"},{"key":"15_CR93_15","first-page":"211a","volume":"100","author":"B Myers","year":"2002","unstructured":"Myers B, Jones SG, McMillan AK et al (2002) Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. Blood 100:211a","journal-title":"Blood"},{"key":"15_CR94_15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624\u2013628","journal-title":"Am J Med"},{"issue":"9","key":"15_CR95_15","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","volume":"106","author":"T Oshima","year":"2005","unstructured":"Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9):3160\u20133165","journal-title":"Blood"},{"key":"15_CR96_15","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin\u2019s Lymphoma \u2013 a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) treatment in multiple myeloma and non-Hodgkin\u2019s lymphoma. Blood 87:2675\u20132682","journal-title":"Blood"},{"key":"15_CR97_15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","volume":"20","author":"A Osterborg","year":"2002","unstructured":"Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Epoetin Beta Hematology Study Group et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486\u20132494","journal-title":"J Clin Oncol"},{"issue":"2","key":"15_CR98_15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","volume":"129","author":"A Osterborg","year":"2005","unstructured":"Osterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129(2):206\u2013209","journal-title":"Br J Haematol"},{"key":"15_CR99_15","first-page":"862","volume":"86","author":"L Pagano","year":"2001","unstructured":"Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, GIMEMA Infection Program, Gruppo Italiano Malattie Ematologiche dell\u2019Adulto et al (2001) Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA infection program. Haematologica 86:862\u2013870","journal-title":"Haematologica"},{"issue":"6","key":"15_CR100_15","first-page":"858","volume":"90","author":"A Palumbo","year":"2005","unstructured":"Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Italian Multiple Myeloma Study Group et al (2005) Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study. Haematologica 90(6):858\u2013860","journal-title":"Haematologica"},{"key":"15_CR101_15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jcp.32.1.56","volume":"32","author":"RB Payne","year":"1979","unstructured":"Payne RB, Carver ME, Morgan DB (1979) Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56\u201360","journal-title":"J Clin Pathol"},{"issue":"8","key":"15_CR102_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00520-003-0477-1","volume":"11","author":"M Pecherstorfer","year":"2003","unstructured":"Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergstrom B (2003) Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 11(8):539\u2013547","journal-title":"Support Care Cancer"},{"key":"15_CR103_15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0277-5379(91)90248-C","volume":"27","author":"D Peest","year":"1991","unstructured":"Peest D, Coldewey R, Deicher H (1991) Overall vs. tumor-related survival in multiple myeloma. Eur J Cancer 27:672","journal-title":"Eur J Cancer"},{"key":"15_CR104_15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K Podar","year":"2001","unstructured":"Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428\u2013435","journal-title":"Blood"},{"issue":"1","key":"15_CR105_15","first-page":"1","volume":"28","author":"C Pozzi","year":"1987","unstructured":"Pozzi C, Pasquali S, Donini U et al (1987) Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol 28(1):1\u20139","journal-title":"Clin Nephrol"},{"key":"15_CR106_15","doi-asserted-by":"crossref","first-page":"ii: 907","DOI":"10.1016\/S0140-6736(85)90848-7","volume":"2","author":"SH Ralston","year":"1985","unstructured":"Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids\/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 2:ii: 907\u2013ii: 910","journal-title":"Lancet"},{"key":"15_CR107_15","first-page":"1741","volume":"112","author":"P Richardson","year":"2008","unstructured":"Richardson P, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff MH et al (2008) Erythropoiesis-stimulating agents do not adversely affect long-term outcomes nor increase the risk of thromboembolic events in multiple myeloma patients treated in the phase III VISTA trial. Blood (ASH Annual Meeting Abstracts) 112:1741","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"15_CR108_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","volume":"26","author":"American Society of Clinical Oncology, American Society of Hematology","year":"2008","unstructured":"Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE, American Society of Clinical Oncology, American Society of Hematology (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update. J Clin Oncol 26(1):132\u2013149. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192","journal-title":"J Clin Oncol"},{"issue":"7","key":"15_CR109_15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","volume":"82","author":"JD Robertson","year":"2000","unstructured":"Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82(7):1261\u20131265","journal-title":"Br J Cancer"},{"issue":"5","key":"15_CR110_15","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377\u2013387","journal-title":"Cancer J"},{"issue":"8","key":"15_CR111_15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735\u20131744","journal-title":"Cancer"},{"key":"15_CR112_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2002.03417.x","volume":"117","author":"S Roux","year":"2002","unstructured":"Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP et al (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:86\u201392","journal-title":"Br J Haematol"},{"key":"15_CR113_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/10428199809050943","volume":"30","author":"P Salutari","year":"1998","unstructured":"Salutari P, Sica S, Laurenti L, Leone F, Chiusolo P, Piccirillo N et al (1998) Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato oncological patients. Leuk Lymphoma 30:193\u2013197","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"15_CR114_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","volume":"67","author":"RM Santaella","year":"2007","unstructured":"Santaella RM, Fraunfelder FW (2007) Ocular adverse effects associated with systemic medications: recognition and management. Drugs 67(1):75\u201393","journal-title":"Drugs"},{"key":"15_CR115_15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","volume":"98","author":"CM Shipman","year":"1997","unstructured":"Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 98:665\u2013672","journal-title":"Br J Haematol"},{"key":"15_CR116_15","first-page":"5294","volume":"58","author":"CM Shipman","year":"1998","unstructured":"Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294\u20135297","journal-title":"Cancer Res"},{"key":"15_CR117_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","volume":"70","author":"F Silvestris","year":"1995","unstructured":"Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313\u2013318","journal-title":"Ann Hematol"},{"key":"15_CR118_15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI116178","volume":"91","author":"A Singh","year":"1993","unstructured":"Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ et al (1993) Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91:251\u2013256","journal-title":"J Clin Invest"},{"key":"15_CR119_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nm0297-151","volume":"3","author":"ES Siris","year":"1997","unstructured":"Siris ES (1997) Breast cancer and osteolytic metastases: can bisphosphonates help? Nat Med 3:151\u2013152","journal-title":"Nat Med"},{"issue":"3","key":"15_CR120_15","first-page":"141","volume":"47","author":"G Sunder-Plassmann","year":"1997","unstructured":"Sunder-Plassmann G, Horl WH (1997) Erythropoietin and iron. Clin Nephrol 47(3):141\u2013157","journal-title":"Clin Nephrol"},{"key":"15_CR121_15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0145-2126(00)00087-4","volume":"25","author":"R Takahashi","year":"2001","unstructured":"Takahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A et al (2001) A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 25:77\u201383","journal-title":"Leuk Res"},{"key":"15_CR122_15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","volume":"49","author":"T Taube","year":"1992","unstructured":"Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192\u2013198","journal-title":"Eur J Haematol"},{"issue":"8","key":"15_CR123_15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","volume":"16","author":"E Terpos","year":"2005","unstructured":"Terpos E, Dimopoulos MA (2005) Myeloma bone disease: pathophysiology and management. Ann Oncol 16(8):1223\u20131231","journal-title":"Ann Oncol"},{"issue":"1","key":"15_CR124_15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","volume":"70","author":"E Terpos","year":"2003","unstructured":"Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C et al (2003) Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70(1):34\u201342","journal-title":"Eur J Haematol"},{"key":"15_CR125_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00355241","volume":"2","author":"B Th\u00fcrlimann","year":"1994","unstructured":"Th\u00fcrlimann B, Morant R, Jungi WF, Radziwill A (1994) Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose\u2013effect study. Support Care Cancer 2:61\u201365","journal-title":"Support Care Cancer"},{"issue":"26","key":"15_CR126_15","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the develop ment of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483\u20132494","journal-title":"N Engl J Med"},{"key":"15_CR127_15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1537-2995.1994.34694295060.x","volume":"34","author":"EC Vamvakas","year":"1994","unstructured":"Vamvakas EC, Taswell HF (1994) Long-term survival after blood transfusion. Transfusion 34:471\u2013477","journal-title":"Transfusion"},{"key":"15_CR128_15","unstructured":"World Health Organization (1990) Cancer pain relief and palliative care: report of a WHO expert panel. WHO Technical Report 804. WHO, Geneva"},{"key":"15_CR129_15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","volume":"116","author":"S Yaccoby","year":"2002","unstructured":"Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278\u2013290","journal-title":"Br J Haematol"},{"issue":"6","key":"15_CR130_15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"K Zervas","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134(6):620\u2013623, Epub 2006 Aug 1","journal-title":"Br J Haematol"},{"issue":"6","key":"15_CR131_15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ki.1988.127","volume":"33","author":"P Zucchelli","year":"1988","unstructured":"Zucchelli P, Pasquali S, Cagnoli L et al (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33(6):1175\u20131180","journal-title":"Kidney Int"}],"container-title":["Recent Results in Cancer Research","Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-540-85772-3_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:52:09Z","timestamp":1741150329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-540-85772-3_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783540857716","9783540857723"],"references-count":132,"URL":"https:\/\/doi.org\/10.1007\/978-3-540-85772-3_15","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"19 March 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}